Press release – For immediate release – 5:45 pm CEST
Half Year Median Technologies liquidity contract statement – First half of 2026
Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of June 30, 2026:
- 37,900 shares
- €184,342.20 in cash.
Transactions during the first half of 2026:
| BUY | 257,824 shares | €1,243,768.89 | 392 transactions |
| SELL | 257,682 shares | €1,270,692.23 | 401 transactions |
For information, as of December 31, 2025, the following resources were listed in the liquidity contract:
- 37,558 shares
- €166,854.84 in cash
As of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:
- 4,404 shares
- €173,829.64 in cash
The daily transaction table is provided in the appendix to this press release (see attached pdf). TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering innovative imaging services and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit